| Yartemlea |
761152 |
001 |
351(a) |
narsoplimab-wuug |
Injection |
Intravenous |
370MG/2ML |
Single-Dose Vial |
2025/12/23
|
Omeros Corporation |
Rx |
Licensed |
N/A |
N/A |
| Lunsumio Velo |
761263 |
003 |
351(a) |
mosunetuzumab-axgb |
Injection |
Subcutaneous |
5MG/0.5ML |
Single-Dose Vial |
2025/12/19
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Lunsumio Velo |
761263 |
004 |
351(a) |
mosunetuzumab-axgb |
Injection |
Subcutaneous |
45MG/ML |
Single-Dose Vial |
2025/12/19
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Boncresa |
761456 |
001 |
351(k) Interchangeable |
denosumab-mobz |
Injection |
Subcutaneous |
60MG/ML |
Pre-Filled Syringe |
2025/12/19
|
Amneal Pharmaceuticals LLC |
Rx |
Licensed |
denosumab |
Prolia |
| Oziltus |
761457 |
001 |
351(k) Interchangeable |
denosumab-mobz |
Injection |
Subcutaneous |
120MG/1.7ML (70MG/ML) |
Single-Dose Vial |
2025/12/19
|
Amneal Pharmaceuticals LLC |
Rx |
Licensed |
denosumab |
Xgeva |
| Nufymco |
761473 |
001 |
351(k) Interchangeable |
ranibizumab-leyk |
Injection |
Intravitreal |
10MG/ML (0.5MG/0.05ML) |
Single-Dose Vial |
2025/12/18
|
Formycon AG |
Rx |
Licensed |
ranibizumab |
Lucentis |
| Nufymco |
761473 |
002 |
351(k) Interchangeable |
ranibizumab-leyk |
Injection |
Intravitreal |
6MG/ML (0.3MG/0.05ML) |
Single-Dose Vial |
2025/12/18
|
Formycon AG |
Rx |
Licensed |
ranibizumab |
Lucentis |
| FESILTY |
125833 |
001 |
351(a) |
fibrinogen, human–chmt |
For Injection |
Intravenous |
1G/50ML |
Single-Dose Vial |
2025/12/16
|
Grifols Therapeutics, LLC |
Rx |
Licensed |
N/A |
N/A |
| Exdensur |
761458 |
001 |
351(a) |
depemokimab-ulaa |
Injection |
Subcutaneous |
100MG/ML |
Autoinjector |
2025/12/16
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Exdensur |
761458 |
002 |
351(a) |
depemokimab-ulaa |
Injection |
Subcutaneous |
100MG/ML |
Pre-Filled Syringe |
2025/12/16
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Lerochol |
761427 |
001 |
351(a) |
lerodalcibep-liga |
Injection |
Subcutaneous |
300MG/1.2ML (250MG/ML) |
Pre-Filled Syringe |
2025/12/12
|
LIB Therapeutics, Inc. |
Rx |
Licensed |
N/A |
N/A |
| waskyra |
125846 |
001 |
351(a) |
etuvetidigene autotemcel |
Solution |
Intravenous |
1.9-11.4x10^6CD34+ CELLS/ML |
Bag |
2025/12/09
|
Fondazione Telethon Ets |
Rx |
Licensed |
N/A |
N/A |
| avance nerve graft |
125816 |
001 |
351(a) |
acellular nerve allograft-arwx |
Implant |
Implantation |
1•LENGTHS: 15 MM, 30 MM, 50 MM, AND 70 MM
•DIAMETERS: 1 TO 2 MM, 2 TO 3 MM, 3 |
Pouch |
2025/12/03
|
Axogen Corporation |
Rx |
Licensed |
N/A |
N/A |
| Omlyclo |
761399 |
003 |
351(k) Interchangeable |
omalizumab-igec |
Injection |
Subcutaneous |
300MG/2ML (150MG/ML) |
Pre-Filled Syringe |
2025/12/01
|
CELLTRION, Inc. |
Rx |
Licensed |
omalizumab |
Xolair |
| Armlupeg |
761212 |
001 |
351(k) Biosimilar |
pegfilgrastim-unne |
Injection |
Subcutaneous |
6MG/0.6ML |
Pre-Filled Syringe |
2025/11/28
|
Lupin Limited (Biotech Division) |
Rx |
Licensed |
pegfilgrastim |
Neulasta |
| Voyxact |
761434 |
001 |
351(a) |
sibeprenlimab-szsi |
Injection |
Subcutaneous |
400MG/2ML (200MG/ML) |
Pre-Filled Syringe |
2025/11/25
|
Otsuka Pharmaceutical Company, Ltd. |
Rx |
Licensed |
N/A |
N/A |
| ITVISMA |
125856 |
001 |
351(a) |
onasemnogene abeparvovec-brve |
Injection |
Intrathecal |
4x10^13VG/ML |
Single-Dose Vial |
2025/11/24
|
Novartis Gene Therapies, Inc. |
Rx |
Licensed |
|
N/A |
| Opdivo Qvantig |
761381 |
002 |
351(a) |
nivolumab and hyaluronidase-nvhy |
Injection |
Subcutaneous |
300MG/2.5ML;5,000UNITS/2.5ML (120MG/2,000UNITS/ML) |
Single-Dose Vial |
2025/11/24
|
Bristol-Myers Squibb Company |
Rx |
Licensed |
N/A |
N/A |
| Poherdy |
761450 |
001 |
351(k) Interchangeable |
pertuzumab-dpzb |
Injection |
Intravenous |
420MG/14ML (30MG/ML) |
Single-Dose Vial |
2025/11/13
|
Shanghai Henlius Biotech, Inc. |
Rx |
Licensed |
pertuzumab |
Perjeta |
| Osvyrti |
761424 |
001 |
351(k) Interchangeable |
denosumab-desu |
Injection |
Subcutaneous |
60MG/ML |
Pre-Filled Syringe |
2025/10/29
|
Accord BioPharma Inc. |
Rx |
Licensed |
denosumab |
Prolia |